Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S. N., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Gu, L., Tan, A., Chao, M., O’Hear, C., Lal, I., Vyas, P., & Daver, N. (2022). S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS. HemaSphere, 6, 67–68. https://doi.org/10.1097/01.hs9.0000843556.59348.1d